MicroPort

The company commenced operations from a small, government-subsidized office in Zhangjiang High-Tech Park and has since grown into a significant player in the global medical technology sector. A key milestone in its history was the acquisition of the Cardiac Rhythm Management (CRM) business from LivaNova PLC in 2018 for $190 million, which led to the formation of MicroPort CRM. This strategic move significantly expanded MicroPort's global footprint, particularly in Europe, and added a portfolio of products for managing heart rhythm disorders. MicroPort CRM now operates primarily from Clamart, France, and Saluggia, Italy.

MicroPort's business model centers on the innovation, manufacturing, and marketing of high-end medical devices across a wide array of segments. Its core markets include Cardiovascular, Orthopedics, Endovascular, Neurovascular, Electrophysiology, and Surgical Management. The company generates revenue through the sale of its diverse product portfolio to thousands of hospitals worldwide. Its offerings range from coronary stents and pacemakers to hip and knee implants. For example, its Firehawk® Rapamycin Target Eluting Coronary Stent is a notable product in its cardiovascular line.

The company serves a global market, with a strong presence in China, the Americas, Europe, and Japan. Through a combination of in-house research and development and strategic acquisitions, MicroPort has diversified its product lines and technological capabilities. The company is publicly traded on the Hong Kong Stock Exchange, a move that provided capital for its continued expansion and R&D efforts. MicroPort's strategy involves creating a global network of specialized companies, each focusing on a specific area of medical technology while benefiting from the parent company's scale and resources.